Haematological Intensive Care
Cross-source consensus on Haematological Intensive Care from 1 sources and 4 claims.
1 sources · 4 claims
Risks & contraindications
Where it comes from
Other
Highlighted claims
- Haematological malignancies account for about 12% of all cancer cases. — Adapted physical activity, exergaming and relaxation by biofeedback in haematological intensive care unit in France: study protocol of a randomised controlled trial (APAER-H trial)
- Treatment for haematological malignancies often involves high-dose cytotoxic therapy, sometimes with haematopoietic stem cell transplantation, in specialised HICUs. — Adapted physical activity, exergaming and relaxation by biofeedback in haematological intensive care unit in France: study protocol of a randomised controlled trial (APAER-H trial)
- Cytotoxic therapy-induced aplasia leaves patients highly vulnerable to infection and bleeding. — Adapted physical activity, exergaming and relaxation by biofeedback in haematological intensive care unit in France: study protocol of a randomised controlled trial (APAER-H trial)
- Sterile isolation during HICU care contributes to physical and psychological harm. — Adapted physical activity, exergaming and relaxation by biofeedback in haematological intensive care unit in France: study protocol of a randomised controlled trial (APAER-H trial)